Andres De Freitas Suarez

Mr. Andres De Freitas Suarez


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Life
Verified
Journal Article
Open access
PDF file
ASAndres De Freitas Suarez
Andres De Freitas Suarez
NENatalia Paola Espinosa
Natalia Paola Espinosa
NANatalia Alvarez-Roger
Natalia Alvarez-Roger
ACArianna Iris Cabrera-Suarez
Arianna Iris Cabrera-Suarez
GJGuillermo Jiménez-Jordán
Guillermo Jiménez-Jordán
JAJanaina Maria Alves
Janaina Maria Alves
HIV-associated neurocognitive disorders (HANDs) continue to impact patients despite antiretroviral therapy. A combination of antiretroviral therapies can diminish the HIV viral load to near undetectable levels, but fails to preserve neurocognitive integrity. The cytokine leukemia inhibitory factor (LIF) has shown neuroprotective properties that could mitigate neurodegeneration in HANDs. The LIF promotes neurogenesis, neural cell differentiation, and survival. Combination antiretroviral therapy reduces severe forms of HANDs, but neurocognitive impairment persists; additionally, some antiretrovirals have additional adverse neurotoxic effects. The LIF counteracts neurotoxic viral proteins and limits neural cell damage in models of neuroinflammation. Adding the LIF as an adjuvant therapy to enhance neuroprotection merits further research for managing HANDs. The successful implementation of the LIF to current therapies would contribute to achieving a better quality of life for the affected population.